Abstract
To the Editor: In their article on effects of suprathreshold levodopa on dyskinesia in advanced Parkinson's disease (PD), Verhagen Metman et al. show that increasing the dose of levodopa will steeply increase both the antiparkinsonian and dyskinetic response until plateau levels are reached.1 Further increase of levodopa dose does not aggravate the severity of dyskinesia, but the antiparkinsonian response duration increases. This implies that in fluctuating patients with disabling end-of-dose parkinsonism, it may be better to bring about improvement by increasing individual levodopa doses rather than fractionating the levodopa doses. This conclusion, however, appears to …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
